The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Skin Complications of Anti-TNF Therapy Common in IBD

Skin Complications of Anti-TNF Therapy Common in IBD

July 31, 2015 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Dermatologic complications hit about one in five patients with inflammatory bowel disease (IBD) on anti-tumor necrosis factor (anti-TNF) therapy, leading to discontinuation of treatment, a French study finds.

You Might Also Like
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Skin Exam Advised Before Anti-TNF-Alpha Therapy

Dr. Laurent Peyrin-Biroulet, from University Hospital of Nancy, and colleagues note that dermatological complications of anti-TNF therapy are known to occur frequently in IBD patients, but until now no study has investigated their incidence, management, and outcome in a large cohort of IBD patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Among 583 IBD patients on anti-TNF therapy seen at their center over 14 years, 176 dermatological complications occurred, involving 20.5% of patients, most commonly psoriasiform (10.1%) and cutaneous (11.6%) lesions, they report in the American Journal of Gastroenterology, online July 21.

At five years, the cumulative incidence of all anti-TNF-induced skin complications was 26%. Younger age at initiation of anti-TNF treatment and Crohn’s disease were significantly associated with a higher risk of skin problems, they found.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At five years, the cumulative incidence of skin infections with anti-TNF therapy was 6.4%, and higher doses were significantly associated with a higher risk.

One in five patients with psoriasiform eruptions stopped taking the anti-TNF agent as a result, but “appropriate and early topical- and/or systemic-specific dermatological therapy can avoid anti-TNF discontinuation in half of patients,” the researchers say.

Psoriasiform lesions recurred in more than half of patients who switched to a different anti-TNF agent. Despite this, the researchers say trying a different agent “should be highly considered before definitive discontinuation.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The key limitation of the study is its single-center retrospective setting and not having systematic prospective skin evaluations in all patients.

“Taken together, our findings could be used to guide decision making in anti-TNF-treated IBD patients developing skin lesions,” the researchers conclude.

Dr. Peyrin-Biroulet did not respond to request for comment by press time.

The study had no funding. Three authors report relationships with pharmaceutical companies including AbbVie, Merck, Pfizer, and Sanofi Aventis.

Filed Under: Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: anti-TNF agent, anti-tumor necrosis factor, Crohn's disease, inflammatory bowel disease, skin disease

You Might Also Like:
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Skin Exam Advised Before Anti-TNF-Alpha Therapy
  • Increased Risk of Serious Infections During Early Anti-TNF Treatment

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)